NEUKIO

Home

About Neukio

Corporate Overview

Development History

Corporate Culture

About Founder

Core Team

R&D

R&D Platform

Process Development

News

Press Releases

BD cooperation

中

About Neukio

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK and CAR-T axis, through internal discovery and external collaboration, with emphasis on innovative immune cell products.

Why iPSC-CAR-NK?

1. NK cells can be universal and readily available (allogeneic use)

2. NK cells can be manufactured in scale via iPSC differentiation and banking

3. Engineered NK have potential to eradicate solid tumors

Gene Editing

NK Diff. & Exp.

Banking

iPSC Bank

News

Press Releases

2024-11-17

China Biotech Industry: Six foreign-invested enterprises gain approval to engage in stem cell research activities

Foreign invested enterprises are gaining greater access to the biotech industry in China.

Press Releases

2024-09-24

【Reprinted from Han Kun Law Offices】China Pilots Lifting Restrictions on Foreign Investment in Stem Cell, Gene Therapy, and Genetic Diagnosis Sectors in Four Free Trade Zones

Press Releases